Year 2024 / Volume 116 / Number 9
Original
FIB-4 score as a predictor of COVID-19-related severity in hospitalized patients

465-471

DOI: 10.17235/reed.2024.9811/2023

Ana Lucena Valera, Rocío Aller de la Fuente, Yolanda Sánchez Torrijos, Manuel Romero Gómez, Javier Ampuero Herrojo,

Abstract
Aim: to determine the impact of liver fibrosis on the prognosis of COVID and liver injury associated with the infection. Methods: retrospective multicenter study including 575 patients requiring admission for COVID-19 between January and June 2020. Fibrosis index-4 (FIB-4) was calculated within six months prior to infection and at six months post-infection. Results: baseline FIB-4 was elevated in patients who died (1.91 ± 0.95 vs 1.43 ± 0.85; p < 0.001). In addition, 17.1 % (32/187) of patients with baseline FIB-4 < 1.45 died vs 52.9 % (9/17) with FIB-4 > 3.25 (p < 0.001). In the adjusted multivariate analysis, baseline FIB-4 (OR 1.61 [95 % CI: 1.19-2.18]; p = 0.002) was independently associated with mortality. Parameters associated with liver injury, including aspartate aminotransferase (AST) (28 ± 10 vs 45 ± 56 IU/l; p < 0.001) and alanine aminotransferase (ALT) (20 ± 12 vs 38 ± 48 IU/l; p < 0.001) were significantly higher at admission compared to baseline. Furthermore, FIB-4 increased from baseline to the time of admission (1.53 ± 0.88 vs 2.55 ± 1.91; p < 0.001), and up to 6.9 % (10/145) of patients with FIB-4 < 1.45 on admission died vs 47.5 % if FIB-4 > 3.25 (58/122) (p < 0.001). In the adjusted multivariate analysis, FIB-4 on admission (OR 1.14 [95 % CI: 1.03-1.27]; p = 0.015) was independently associated with mortality. In addition, AST (42 ± 38 vs 22 ± 17 IU/l; p < 0.001) and ALT (40 ± 50 vs 20 ± 19 IU/l; p < 0.001) were significantly reduced at six months after the resolution of infection. Accordingly, FIB-4 decreased significantly (2.12 ± 1.25 vs 1.32 ± 0.57; p < 0.001) six months after the infection. Conclusion: increased FIB-4, either at baseline or at the time of admission, was associated with severity and mortality related to respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, the liver damage expressed by elevated transaminases and FIB-4 levels was reversible in most of patients.
Lay Summary
The prevalence of abnormal liver function tests in COVID-19 patients has been reported to range from 15% to 70%. In this setting, liver fibrosis could be a relevant factor in the natural history of COVID-19. FIB-4 is a simple four-variable tool (including AST, ALT, age, and platelet) for estimating liver fibrosis. In our study, we observed that patients with increased FIB-4 had a higher severity and mortality related to SARS-CoV-2 infection. The early identification of high-risk patients could improve patient care and prognosis of SARS-CoV-2 infection.
Share Button
New comment
Comments
No comments for this article
References
1. Gato S, Lucena-Valera A, Muñoz-Hernández R, et al. Impact of COVID-19 on liver disease: From the experimental to the clinic perspective. World J Virol. 2021;10(6):301-311.
2. Bloom PP, Meyerowitz EA, Reinus Z, et al. Liver Biochemistries in Hospitalized Patients With COVID-19. Hepatology. 202173(3):890-900.
3. Hundt MA, Deng Y, Ciarleglio MM, et al. Abnormal Liver Tests in COVID-19: A Retrospective Observational Cohort Study of 1,827 Patients in a Major U.S. Hospital Network. Hepatology. 2020;72(4):1169-1176.
4. Ampuero J, Romero Gómez M. COVID-19 and the liver: the chicken or the egg dilemma. Rev Esp Enferm Dig. 2021;113(7):555.
5. Ampuero J, Lucena A, Hernández-Guerra M, et al. Primary biliary cholangitis and SARS-CoV-2 infection: incidence, susceptibility and outcomes. Gut. 2021; 7:gutjnl-2021-325700.
6. Sterling RK, Lissen E, Clumeck N, el at. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317-25.
7. Vilar-Gomez E, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. Journal of Hepatology. 2018;68(2):305-15.
8. Crisan D, Avram L, Grapa C, et al. Liver Injury and Elevated FIB-4 Define a High-Risk Group in Patients with COVID-19. J Clin Med. 2021 28;11(1):153.
9. Li Y, Regan J, Fajnzylber J, Coxen K, et al. Liver Fibrosis Index FIB-4 Is Associated With Mortality in COVID-19. Hepatol Commun. 2021;5(3):434-445.
10. Pranata R, Yonas E, Huang I, et al. Fibrosis-4 index and mortality in coronavirus disease 2019: a meta-analysis. Eur J Gastroenterol Hepatol. 2021; 1;33(S1):368-374.
11. Ibáñez-Samaniego L, Bighelli F, Usón C, et al. Elevation of Liver Fibrosis Index FIB-4 Is Associated With Poor Clinical Outcomes in Patients With COVID-19. J Infect Dis. 2020; 222(5):726-733.
12. APASL COVID Task Force, APASL COVID Liver Injury Spectrum Study (APCOLIS Study-NCT 04345640), Sarin SK, et al. Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study). Hepatol Int; 2020;14(5):690-700.
13. Wang Y, Hu M, Yang H. Cirrhosis is an independent predictor for COVID-19 mortality: A meta-analysis of confounding cofactors-controlled data. J Hepatol. 2023;78(1):28-31
14. Bertolini A, van de Peppel IP, Bodewes F, et al. Abnormal Liver Function Tests in Patients With COVID-19: Relevance and Potential Pathogenesis. Hepatology. 2020;72(5):1864-1872.
15. Levin AT, Hanage WP, Owusu-Boaitey N, et al. Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications. Eur J Epidemiol. 2020;35(12):1123-1138.
16. Chen LY, Chu HK, Bai T, et al. Liver damage at admission is an independent prognostic factor for COVID-19. J Dig Dis 2020;21:512-518.
17. Ampuero J, Sánchez-Torrijos Y, García Lozano MR, et al. Impact of liver injury on the severity of COVID-19: Systematic Review with Meta-analysis. Rev Esp Enferm Dig. 2020; 113(2):125-135.
18. Fu L, Wang B, Yuan T, et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and meta-analysis. J Infect. 2020;80(6):656-665.
19. Canillas L, Broquetas T, Carrión JA, et al. Follow-up evaluation of patients with liver test abnormalities detected during SARS-CoV2 infection. J Viral Hepat. 2022;29(9):823-834.
Related articles

Letter

Autoimmune hepatitis after SARS-C¬¬oV-2 vaccination

DOI: 10.17235/reed.2023.9579/2023

Digestive Diseases Image

Endosonographic and ERCP findings in COVID-19 critical illness cholangiopathy

DOI: 10.17235/reed.2022.9218/2022

Letter

Infection with SARS-CoV-2 as a potential achalasia trigger

DOI: 10.17235/reed.2022.8975/2022

Digestive Diseases Image

Acute respiratory failure secondary to megaesophagus: think beyond COVID-19

DOI: 10.17235/reed.2022.8847/2022

Letter

COVID-19 vaccine and autoimmune hepatitis

DOI: 10.17235/reed.2022.8837/2022

Letter

SARS-CoV-2 vaccine, a new autoimmune hepatitis trigger?

DOI: 10.17235/reed.2022.8820/2022

Letter

Surgical acute abdomen and COVID-19 vaccination

DOI: 10.17235/reed.2022.8721/2022

Letter

AMA-positive hepatitis induced by the SARS-CoV-2 vaccine.

DOI: 10.17235/reed.2022.8533/2021

Letter

A case of COVID-19 with concomitant infection with hepatitis A

DOI: 10.17235/reed.2021.8372/2021

Letter

COVID-19 and aorto-enteric fistula

DOI: 10.17235/reed.2021.8272/2021

Digestive Diseases Image

Portal thrombosis in a patient with SARS-CoV-2 infection

DOI: 10.17235/reed.2021.8099/2021

Letter

Autoimmune hepatitis triggered by COVID-19

DOI: 10.17235/reed.2021.8045/2021

Letter

Pneumoperitoneum and COVID-19. A causal association?

DOI: 10.17235/reed.2021.7877/2021

Letter

COVID-19 and the liver: the chicken or the egg dilemma

DOI: 10.17235/reed.2021.7861/2021

Letter

Acute pancreatitis related to SARS-CoV-2 infection. Disclaimer

DOI: 10.17235/reed.2021.7853/2021

Letter

Pancreatic injury and acute pancreatitis in COVID-19 patients

DOI: 10.17235/reed.2021.7807/2021

Editorial

Leading in turbulent times with the aim to serve

DOI: 10.17235/reed.2020.7684/2020

Letter

Pancreatic injury in COVID-19: pathogenesis and challenges

DOI: 10.17235/reed.2020.7541/2020

Letter

SARS-CoV-2 and acute pancreatitis: a new etiological agent?

DOI: 10.17235/reed.2020.7481/2020

Letter

Latin American authorship in scientific production on COVID-19

DOI: 10.17235/reed.2020.7432/2020

Letter

COVID-19. Immunothrombosis and the gastrointestinal tract

DOI: 10.17235/reed.2020.7292/2020

Letter

The effect of Adacolumn® on ulcerative colitis with COVID-19

DOI: 10.17235/reed.2020.7156/2020

Rapid reviews

COVID-19, coronavirus, SARS-CoV-2 and the small bowel

DOI: 10.17235/reed.2020.7137/2020

Citation tools
Lucena Valera A, Aller de la Fuente R, Sánchez Torrijos Y, Romero Gómez M, Ampuero Herrojo J. FIB-4 score as a predictor of COVID-19-related severity in hospitalized patients. 9811/2023


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 442 visits.
This article has been downloaded 38 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 30/06/2023

Accepted: 26/04/2024

Online First: 20/05/2024

Published: 09/09/2024

Article revision time: 285 days

Article Online First time: 325 days

Article editing time: 437 days


Share
This article hasn't been rated yet.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology